Liraglutide is effective for weight loss and blood sugar control, but is less potent than newer GLP-1 medications such as semaglutide (Ozempic, Wegovy, and Rybelsus) and tirzepatide (Mounjaro and Zepbound), which provide greater weight loss and better sugar control
Limitations of Current Fat Loss Research While promising, research on AOD-9604 has limitations: Preclinical focus: Researchers base most findings on in vitro or animal models, with limited human data available
(Explains that compounded medications under Section 503A are exempt from FDA pre-market approval requirements, meaning their safety and efficacy are not evaluated by FDA prior to use)
Since its development, AOD-9604 has been the subject of over 16 peer-reviewed publications spanning three decades, including six randomized, double-blind, placebo-controlled human clinical trials involving more than 900 participants